DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,376,170 | +3.3% | 25,700 | -0.1% | 0.90% | +8.6% |
| Q2 2023 | $6,173,280 | -61.7% | 25,722 | -59.8% | 0.82% | -61.4% |
| Q1 2023 | $16,120,982 | -22.8% | 63,962 | -18.7% | 2.14% | -23.7% |
| Q4 2022 | $20,890,412 | +2.3% | 78,707 | -0.4% | 2.80% | +1.0% |
| Q3 2022 | $20,420,000 | +1.4% | 79,057 | -0.4% | 2.77% | +5.4% |
| Q2 2022 | $20,129,000 | -23.2% | 79,401 | -11.2% | 2.63% | +0.7% |
| Q1 2022 | $26,217,000 | -11.0% | 89,377 | -0.1% | 2.61% | -0.8% |
| Q4 2021 | $29,443,000 | +7.8% | 89,492 | -0.3% | 2.63% | +2.4% |
| Q3 2021 | $27,316,000 | -20.1% | 89,727 | -29.5% | 2.57% | +7.4% |
| Q2 2021 | $34,174,000 | +13.5% | 127,342 | -4.8% | 2.39% | +5.4% |
| Q1 2021 | $30,107,000 | -6.4% | 133,765 | -7.6% | 2.27% | -1.0% |
| Q4 2020 | $32,160,000 | +0.2% | 144,776 | -2.9% | 2.29% | -8.2% |
| Q3 2020 | $32,109,000 | -7.7% | 149,113 | -24.2% | 2.50% | +5.4% |
| Q2 2020 | $34,776,000 | +30.3% | 196,661 | +2.0% | 2.37% | +10.5% |
| Q1 2020 | $26,679,000 | -11.0% | 192,756 | -1.3% | 2.14% | +9.7% |
| Q4 2019 | $29,966,000 | +20.3% | 195,240 | +13.2% | 1.95% | +5.0% |
| Q3 2019 | $24,906,000 | -11.1% | 172,442 | -12.1% | 1.86% | +4.1% |
| Q2 2019 | $28,031,000 | -3.2% | 196,130 | -10.5% | 1.79% | -14.4% |
| Q1 2019 | $28,945,000 | +19.2% | 219,246 | -6.9% | 2.09% | +6.0% |
| Q4 2018 | $24,281,000 | -9.3% | 235,472 | -4.4% | 1.97% | +15.9% |
| Q3 2018 | $26,768,000 | +7461.6% | 246,342 | +6761.9% | 1.70% | +7291.3% |
| Q2 2018 | $354,000 | -6.6% | 3,590 | -7.2% | 0.02% | +4.5% |
| Q1 2018 | $379,000 | 0.0% | 3,870 | -5.1% | 0.02% | +15.8% |
| Q4 2017 | $379,000 | +8.3% | 4,080 | 0.0% | 0.02% | +35.7% |
| Q3 2017 | $350,000 | -5.4% | 4,080 | -6.8% | 0.01% | 0.0% |
| Q2 2017 | $370,000 | -1.3% | 4,380 | 0.0% | 0.01% | 0.0% |
| Q1 2017 | $375,000 | +10.0% | 4,380 | 0.0% | 0.01% | +7.7% |
| Q4 2016 | $341,000 | -8.3% | 4,380 | -7.8% | 0.01% | 0.0% |
| Q3 2016 | $372,000 | -25.5% | 4,750 | -3.8% | 0.01% | -45.8% |
| Q2 2016 | $499,000 | +6.4% | 4,940 | 0.0% | 0.02% | +4.3% |
| Q1 2016 | $469,000 | -11.2% | 4,940 | -13.2% | 0.02% | -4.2% |
| Q4 2015 | $528,000 | -1.3% | 5,690 | -9.4% | 0.02% | -7.7% |
| Q3 2015 | $535,000 | +57.4% | 6,280 | +58.2% | 0.03% | +73.3% |
| Q2 2015 | $340,000 | -4.5% | 3,970 | -5.3% | 0.02% | +7.1% |
| Q1 2015 | $356,000 | +102.3% | 4,190 | +104.4% | 0.01% | +100.0% |
| Q4 2014 | $176,000 | -9.7% | 2,050 | -17.3% | 0.01% | -12.5% |
| Q2 2014 | $195,000 | -1.5% | 2,480 | -6.1% | 0.01% | 0.0% |
| Q1 2014 | $198,000 | -26.9% | 2,640 | -24.8% | 0.01% | -27.3% |
| Q4 2013 | $271,000 | +108.5% | 3,510 | +87.7% | 0.01% | +83.3% |
| Q3 2013 | $130,000 | +10.2% | 1,870 | 0.0% | 0.01% | 0.0% |
| Q2 2013 | $118,000 | – | 1,870 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |